Novavax-Serum Institute Vaccine Gets Emergency Use Approval In Indonesia

The vaccine will be manufactured by Serum Institute of India (SII) in India and marketed by it in Indonesia under the brand name Covovax, Novavax Inc said in a statement.

Biotechnology firm Novavax Inc and its partner Serum Institute of India on Monday said they have received the first emergency use authorisation (EUA) for Novavax's COVID-19 vaccine, in Indonesia.

The vaccine will be manufactured by Serum Institute of India (SII) in India and marketed by it in Indonesia under the brand name Covovax, Novavax Inc said in a statement.

"The National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Peng was Obat dan Makanan (Badan POM), has granted emergency use authorisation (EUA) for Novavax'' recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant," it added.

Initial shipments into Indonesia are expected to begin imminently, the statement said.